InnovAge (INNV) Stock Price, News & Analysis

Company Overview

InnovAge Holdings, Inc. (NASDAQ:INNV) is a healthcare services company that specializes in caring for seniors through the Program of All-Inclusive Care for the Elderly (PACE). Designed for individuals who are eligible for both Medicare and Medicaid, the PACE model integrates medical care, social services and long-term care—delivered primarily in participants’ homes and community-based centers. InnovAge’s approach centers on interdisciplinary care teams that coordinate everything from primary and specialty medical services to nutritional counseling and recreational activities.

The company’s core offerings include comprehensive in-home assessments, physician and nursing services, physical and occupational therapy, prescription medication management, and transportation to medical appointments. InnovAge also manages adult day health centers where participants can receive social engagement activities, meals and group therapy sessions. By combining preventive care and chronic disease management with supportive social services, InnovAge aims to reduce hospitalizations and nursing home admissions among high-risk seniors.

Founded in 2014 and headquartered in Denver, Colorado, InnovAge operates a network of PACE centers across California, Colorado and Texas. The company serves urban and rural communities, adapting its care delivery model to address regional demographics and healthcare infrastructure. Supported by a management team with extensive experience in geriatrics, community health and healthcare operations, InnovAge continues to expand its footprint while maintaining regulatory compliance and quality standards set by state and federal authorities.

Key Stats

• Today's Range: $4.53 to $5.11
• 50-Day Range: $3.13 to $5.18
• 52-Week Range: $2.60 to $6.69
• Volume: 102,325 shs
• Average Volume: 41,955 shs
• Market Capitalization: $628.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Reduce

InnovAge Stock Analysis - MarketRank™

InnovAge scored higher than 18% of companies evaluated by MarketBeat, and ranked 864th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.6 / 5
• Analyst Rating: Reduce

Consensus Rating

InnovAge has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for InnovAge is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

InnovAge has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for InnovAge are expected to grow in the coming year, from ($0.12) to $0.06 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InnovAge is -20.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of InnovAge is -20.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

InnovAge has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.60% of the float of InnovAge has been sold short.

Short Interest Ratio / Days to Cover

InnovAge has a short interest ratio ("days to cover") of 9.3.

Change versus previous month

Short interest in InnovAge has recently decreased by 3.13%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InnovAge does not currently pay a dividend.

Dividend Growth

InnovAge does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.60% of the float of InnovAge has been sold short.

Short Interest Ratio / Days to Cover

InnovAge has a short interest ratio ("days to cover") of 9.3.

Change versus previous month

Short interest in InnovAge has recently decreased by 3.13%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.53

News Sentiment

InnovAge has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for InnovAge this week, compared to 1 article on an average week.

Search Interest

1 people have searched for INNV on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added InnovAge to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InnovAge insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.40% of the stock of InnovAge is held by insiders.

Percentage Held by Institutions

Only 12.26% of the stock of InnovAge is held by institutions.

INNV Stock Analysis - Frequently Asked Questions

How have INNV shares performed this year?

InnovAge's stock was trading at $3.93 at the beginning of the year. Since then, INNV shares have increased by 17.8% and is now trading at $4.63.

How were InnovAge's earnings last quarter?

InnovAge Holding Corp. (NASDAQ:INNV) issued its earnings results on Tuesday, September, 9th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.02) by $0.01. The business earned $221.42 million during the quarter, compared to analysts' expectations of $219.80 million. InnovAge had a negative trailing twelve-month return on equity of 12.02% and a negative net margin of 3.55%.
Read the conference call transcript.

When did InnovAge IPO?

InnovAge (INNV) raised $301 million in an IPO on Thursday, March 4th 2021. The company issued 16,700,000 shares at $17.00-$19.00 per share. J.P. Morgan, Barclays, Goldman Sachs and Citigroup served as the underwriters for the IPO and Baird, William Blair, Piper Sandler, Capital One Securities, Loop Capital Markets, Siebert Williams Shank and Roberts & Ryan were co-managers.

Who are InnovAge's major shareholders?

InnovAge's top institutional shareholders include Kent Lake PR LLC (1.26%), Geode Capital Management LLC (0.41%), Welch Capital Partners LLC NY (0.33%) and Winnow Wealth LLC (0.07%). Insiders that own company stock include Nicole Damato, Richard C Zoretic, Richard C Zoretic and Michael Anthony Scarbrough.
View institutional ownership trends.

How do I buy shares of InnovAge?

Shares of INNV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InnovAge own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InnovAge investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 9/09/2025
• Today: 9/21/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:INNV
• CIK: 1834376
• Web: www.innovage.com
• Phone: 844-803-8745
• Fax: N/A
• Employees: 2,440
• Year Founded: N/A

Price Target and Rating

• Average Price Target for InnovAge: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +8.0%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.31 million
• Net Margins: -3.55%
• Pretax Margin: -3.99%
• Return on Equity: -12.02%
• Return on Assets: -5.73%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 1.07
• Quick Ratio: 1.07

Sales & Book Value

• Annual Sales: $853.70 million
• Price / Sales: 0.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.76 per share
• Price / Book: 2.63

Miscellaneous

• Outstanding Shares: 135,640,000
• Free Float: 133,739,000
• Market Cap: $628.01 million
• Optionable: Optionable
• Beta: 0.52